# A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study

> **NCT02049112** · PHASE4 · COMPLETED · sponsor: **Unither Pharmaceuticals, France** · enrollment: 210 (actual)

## Conditions studied

- Xerostomia
- Hyposalivation
- Head and Neck Cancer
- Sjögren Syndrome

## Interventions

- **DEVICE:** Salivary equivalent
- **DEVICE:** Aequasyal
- **DEVICE:** Biotene

## Key facts

- **NCT ID:** NCT02049112
- **Lead sponsor:** Unither Pharmaceuticals, France
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2013-04
- **Final completion:** 2013-06
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2014-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02049112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02049112, "A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02049112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*